GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » Financial Strength

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Financial Strength : 3 (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Freeline Therapeutics Holdings Financial Strength?

Freeline Therapeutics Holdings has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate Freeline Therapeutics Holdings's interest coverage with the available data. Freeline Therapeutics Holdings's debt to revenue ratio for the quarter that ended in Sep. 2023 was 199.40. As of today, Freeline Therapeutics Holdings's Altman Z-Score is -15.87.


Competitive Comparison of Freeline Therapeutics Holdings's Financial Strength

For the Biotechnology subindustry, Freeline Therapeutics Holdings's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Freeline Therapeutics Holdings's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Freeline Therapeutics Holdings's Financial Strength distribution charts can be found below:

* The bar in red indicates where Freeline Therapeutics Holdings's Financial Strength falls into.



Freeline Therapeutics Holdings Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Freeline Therapeutics Holdings's Interest Expense for the months ended in Sep. 2023 was $0.00 Mil. Its Operating Income for the months ended in Sep. 2023 was $-12.03 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $1.70 Mil.

Freeline Therapeutics Holdings's Interest Coverage for the quarter that ended in Sep. 2023 is

GuruFocus does not calculate Freeline Therapeutics Holdings's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Freeline Therapeutics Holdings PLC has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Freeline Therapeutics Holdings's Debt to Revenue Ratio for the quarter that ended in Sep. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Sep. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.286 + 1.702) / 0.02
=199.40

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Freeline Therapeutics Holdings has a Z-score of -15.87, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -15.87 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Freeline Therapeutics Holdings  (NAS:FRLN) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Freeline Therapeutics Holdings has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.


Freeline Therapeutics Holdings Financial Strength Related Terms

Thank you for viewing the detailed overview of Freeline Therapeutics Holdings's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
Gunnels Wood Road, Sycamore House, Stevenage, Hertfordshire, GBR, SG1 2BP
Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.